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The PSORS1 locus in the major histocompatibility
complex region is the major genetic determinant for
psoriasis vulgaris. Within the PSORS1 region reside at
least three potential candidate genes for psoriasis sus-
ceptibility. Speci¢c allelic variants of the genes HLA-
Cwn6, HCRnWWCC, and CDSNn5 are strongly asso-
ciated with psoriasis vulgaris and are in strong linkage
disequilibrium with each other.We have genotyped the
three psoriasis vulgaris susceptibility alleles of the
PSORS1 locus in two clinical variants of psoriasis (gut-
tate psoriasis and palmoplantar pustulosis) to study
whether PSORS1 is also involved in the pathogenesis
of these variants. We also asked whether these two
clinical subgroups could help us to distinguish the cau-
sative gene within the high-risk PSORS1 haplotype.
The association of guttate psoriasis with the three
PSORS1 susceptibility alleles was similar and even
stronger than seen with psoriasis vulgaris. Palmoplan-
tar pustulosis, however, did not show association with
any of the three candidate genes at this locus. Finally,
no correlation with the age of onset for disease was ob-
served. Our results show conclusively that psoriasis vul-
garis and guttate psoriasis have a similar genetic basis
for their association to PSORS1, whereas palmoplantar
pustulosis appears to be a distinct disorder. Key words:
Psoriasis/pustulosis/PSORS1/HLA-C/corneodesmosis/HCR.
J Invest Dermatol 120:627 ^632, 2003
P
soriasis is a chronic in£ammatory skin disease. All ma-
jor human populations are a¡ected with a peak preva-
lence of 2^3% observed in north European Caucasians
(Christophers, 2001).Whereas the disease is rarely fatal,
it clearly has a potentially devastating e¡ect on the pa-
tient’s quality of life. Furthermore, present treatments are essen-
tially palliative and are either cosmetically unacceptable or
possess signi¢cant toxic side-e¡ects.
The most common form, psoriasis vulgaris (PV), accounts for
approximately 85% of all cases and is characterized clinically by
well-de¢ned, red, indurated, scaly plaques that may be limited or
widespread in extent. Population, family, and twin studies indi-
cate that this form has a genetic basis. Multiple independent gen-
ome-wide scans have been performed revealing a number of
linked genetic loci, seven of which achieve statistical signi¢cance
(reviewed recently by Capon et al, 2002). Of these, a locus within
the major histocompatibility complex on chromosome 6p
(PSORS1) has been consistently replicated (Nair et al, 1997;
Trembath et al, 1997; Burden et al, 1998) and is estimated to ac-
count for 35^50% of the genetic risk to psoriasis. Association
studies have localized the high-risk allele to an approximately
200 kb region at the centromeric end of class I major histocom-
patibility complex (Balendran et al, 1999; Oka et al, 1999; Nair
et al, 2000).Within this region are at least three potential candi-
date genes for psoriasis susceptibility: the class 1 gene HLA-C,
HCR (a helical coiled coil rod protein), and CDSN (corneodes-
mosin). Speci¢c allelic variants, HLA-Cwn6 (Tiilikainen et al,
1980; Asahina et al, 1991; Mallon et al, 1997), HCRnWWCC
(Asumalahti et al, 2000, 2002), and CDSNn5 (Allen et al, 1999;
Jenisch et al, 1999; Tazi-Ahnini et al, 1999a) are strongly associated
with PV and are also in strong linkage disequilibrium with each
other. Indeed, recent studies considering all three genes or haplo-
types in the PSORS1 region among large family collections have
suggested that separation of their genetic e¡ects will require very
large association studies (Nair et al, 2000; Asumalahti et al, 2002;Veal
et al, 2002).
Guttate psoriasis (GP), an important clinical variant, most fre-
quently occurs in adolescents and young adults. It is characterized
by the sudden onset of widely dispersed small red scaly plaques
mainly over the trunk and proximal limbs. GP is often associated
with a preceding streptococcal throat infection or a rise in
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anti-streptococcal serum titer (Telfer et al, 1992; Mallon et al, 2000).
In most cases the disease is self-limiting (acute GP), but a signi¢-
cant proportion of the patients develop PV later in life. These indi-
viduals often have a family history of psoriasis (Naldi et al, 2001).
Guttate £ares in patients with established PV are also frequently
observed. These observations, taken together with investigative
studies, indicate an important pathogenetic link between GP and PV.
Palmoplantar pustulosis (PPP) is characterized by sterile pus-
tules localized in the lowest part of stratum corneum and erythe-
matous, scaly skin con¢ned to the palms and soles. PPP has some
common features with other pustular forms of psoriasis and is
often classi¢ed as a localized form of pustular psoriasis (Lever
and Schaumburg-Lever, 1990; Camp, 1998). The relationship be-
tween PPP and psoriasis, however, is controversial. Up to 24%
of PPP patients have psoriasis (Enfors and Molin, 1971), which is
much higher than the normal population prevalence of psoriasis.
The histology of the skin lesions of PPP and other pustular forms
of psoriasis share many common features such as spongiform
pustules and a mononuclear in£ammatory in¢ltrate (Lever
and Schaumburg-Lever, 1990). PPP is a relatively rare disorder
with a prevalence of 0.01^0.05% (Lomholt, 1963; Hellgren and
Mobacken, 1971). The age of onset is usually between 30 and 50
y (Enfors and Molin, 1971; Hellgren and Mobacken, 1971; Eriks-
son et al, 1998). PPP is more common in females, with a sex ratio
4.6^11.5 (Hellgren and Mobacken, 1971; Eriksson et al, 1998) and
strongly associated with tobacco smoking (Rosen et al, 1982;
Akiyama et al, 1995). The disease is persistent and painful, leading
to a considerable functional impairment (Enfors and Molin, 1971;
Hellgren and Mobacken, 1971). Treatment is di⁄cult, requiring in
some patients systemic therapy.
Genetic studies of GP and PPP are few in number, typically of
small cohort size, and limited to the major histocompatibility
complex. Like PV, GP has been associated with HLA-Cwn6
(Mallon et al, 2000) and CDSNn5 (Tazi-Ahnini et al, 1999b). No
consistent major histocompatibility complex associations have
been reported for PPP (Karvonen et al, 1975; Zachariae et al, 1977;
Ward and Barnes, 1978; Rosen et al, 1982).
This study was undertaken to determine the role of the
PSORS1 locus in the clinical variants of psoriasis, GP and PPP.
We attempted to answer two important questions: Is PSORS1,
and in particular the new candidate gene HCR involved in the
pathogenesis of GP and PPP? Can the study of GP and PPP
help to distinguish the causative gene within the high-risk
PSORS1 haplotype, bearing the HLA-Cwn6, HCRnWWCC,
and CDSNn5 alleles?
MATERIALS AND METHODS
Study population PPP and GP patients were recruited from three
dermatology centers in the UK: London, Manchester, and Glasgow. An
experienced dermatologist at each center veri¢ed the diagnosis according
to a set of standard clinical criteria, and common data sheets were used
for patient ascertainment (Camp, 1998). Unrelated patients with GP
(n¼134) were assigned to one of two distinct subgroups depending on
their clinical history and examination: acute GP (n¼ 64, 48%) alone or
guttate £are of PV (n¼ 56, 42%). Fourteen patients could not be classi¢ed
into either of the groups. Unrelated patients with PPP (n¼106) were
examined for concomitant PV and 19 patients (18%) had both PV and
PPP (Table I). The mean age of onset for PPP was 51 y and the female/
male ratio was 4.6. DNA samples for the control population (n¼ 309, 124
male and 182 female, three unknown) were obtained from two primary
sources: Tissue Typing Laboratory (n¼144), and volunteers recruited from
sta¡ (n¼165) both at Guy’s and St Thomas’ Hospitals, London, UK.
A second PPP sample set of 50 patients was collected from Sweden. The
clinical details of most patients have been described elsewhere (Eriksson
et al, 1998). Nine patients (18%) had concomitant PV. The mean age at
onset was 42 y and the female/male ratio was 11.5 (Table I). The collection
of all samples was by informed consent and approved by local ethical
review committees for both patients and controls.
Genotyping We genotyped ¢rst the UK samples, 134 GP and 106 PPP
patients together with 309 una¡ected population-matched controls for the
HLA-C locus, for ¢ve CDSN SNP (þ619,þ1215,þ1236,þ1240,þ1243)
and for 10 HCR SNP (þ 305,þ307,þ325,þ492,þ825,þ1099,þ1249,
þ 1285,þ1723,þ 2327). The CDSN SNPþ 619 T,þ1240 G, andþ1243 C
de¢ned the CDSNn5 allele and the HCR SNPþ 307 T,þ325 T,þ1723 T,
andþ 2327 G de¢ned the HCRnWWCC allele. In addition, two SNP
centromeric to HLA-C, SNP 7 and SNP 9 (Veal et al, 2002) were
genotyped. The HLA-C locus was genotyped using single strand
conformation polymorphism^polymerase chain reaction (Tonks et al,
1999) and all the other SNP were genotyped using allele-speci¢c
hybridization assay (Je¡reys et al, 2000). The 50 Swedish PPP patients were
genotyped for four HCR SNP and the HLA-Cwn6 allele using polymerase
chain reaction ampli¢cation and altered restriction site recognizing
enzymes as described earlier (Asumalahti et al, 2002). DNA for the
genotyping was extracted from venous blood samples using a standard
nonenzymatic procedure.
To discover possible new polymorphisms of the HCR gene speci¢c for
PPP, we sequenced eight British and six Swedish PPP patients for the
HCR gene coding region using direct sequencing from polymerase chain
reaction products ampli¢ed using intronic primers as described earlier
(Asumalahti et al, 2000).
Statistical analysis We calculated odds ratios [OR¼ f(a¡)/(1 
f(a¡)):f(contr)/(1  f(contr))] with 95% con¢dence intervals (95% CI) and
allele associations for all the individual SNP and for the HLA-C alleles.
For each allele, only individuals who had genotyping data for that allele
were counted. The statistical signi¢cance between the case and control
groups was calculated using the w2-test or alternatively Fisher’s exact test,
when the number of expected observations was less than ¢ve. Bonferroni
correction for multiple testing was applied to reduce type I error.
Immunohistochemistry Skin specimens were obtained from GP
(n¼ 6), PPP in various stages (n¼ 20), and from healthy control sole skin
(n¼ 7). Histologic diagnosis was con¢rmed by an experienced
dermatopathologist. Immunostaining was performed on formalin-¢xed
para⁄n-embedded specimens as previously described using a⁄nity-
puri¢ed polyclonal HCR antibodies, aminoethylcarbazole as chromogen,
and hematoxylin as counterstain (Asumalahti et al, 2002). Control
stainings were performed with preimmune serum. Stained specimens
were analyzed qualitatively by light microscopy.
RESULTS
Genotyping Altogether, we genotyped 134 British GP
patients, 106 PPP patients, and 309 una¡ected population-
matched controls for HLA-C, ¢ve CDSN SNP, 10 HCR SNP,
and two noncoding SNP close to HLA-C. In addition, 50
Swedish PPP patients were genotyped for the HLA-Cwn6 and
HCRnWWCC allele de¢ning SNP. We calculated case^control
OR and allele association tests for all the individual SNP and
for the HLA-C alleles. Unambiguous haplotyping was not
possible because all the samples were from individuals without
family members hence haplotypes were predicted from
population data using the PHASE 1.0 program (Stephens et al,
2001).
GP was strongly associated with HLA-Cwn6. Eighty-three
percent (105 of 126) of all GP patients had the Cwn6 allele
and only 15% (47 of 307) of controls (OR¼ 27.7, 95%
CI¼15.8^48.5, p¼ 410^40) (Table II). There was no di¡erence
in the Cwn6 allele frequency between the two GP subgroups,
acute guttate and guttate £are. None of the other HLA-C alleles
Table I. Demographic details of patients
Total no.
of patients
No of
females
Mean age,
years (range)
Mean age
of onset,
years
Guttate patients (all from U.K.)
Acute guttate 64 35 (55%) 27 (11^52) 17
Guttate £are 56 31 (55%) 35 (15^70) 18
PPP patients
from U.K. 106 87 (82%) 58 (32^89) 51
from Sweden 50 46 (92%) 54 (28^76) 42
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showed association in GP patients. SNPn7 A and SNPn9 C
also showed a strong association with GP. The frequencies of
the alleles were 85% in patients and 20^21% in controls
(OR¼ 23.7, 95%CI¼13.0^43.0, p¼ 910^32 andOR¼ 22.0, 95%
CI¼12.1^40.2, p¼ 710^30, respectively). The CDSN-1243nC
allele was more common in GP patients than in controls 98% vs
75% (OR¼14.1, 95% CI¼ 4.4^45.7, p¼ 410^7), but it was the
major allele in both groups. All four HCR SNP de¢ning the
HCRnWWCC allele (HCR-307nT, HCR-325nT, HCR-1723nT,
HCR-2327nG) associated signi¢cantly with GP, and the
associations were stronger than for CDSN. The frequencies of
these alleles were over 90% in GP patients and only about 40%
in controls (OR¼ 7.2^20.6, 95% CI¼ 3.9^43.7, p-values ranging
from 110^10 to 210^21) (Table III). HCR-492nG, HCR-
1249nT, and HCR-1285nT alleles belong to the HCR PSORS1
susceptibility haplotype, but are not unique to it and showed
weaker association.
Eighty-six percent of guttate patients and only 31% of controls
had all four susceptibility SNP alleles of HCRnWWCC
(OR¼13.6, 95% CI¼ 7.7^24.1, p¼ 910^23). Almost all of the
GP patients had CDn5 forming SNP alleles, but the CDn5 was
more common also in controls (OR¼11.9, 95% CI¼ 6.1^22.9,
93% vs 47%, p¼ 210^17). Assessment of the two GP
subgroups separately revealed that the HCRnWWCC SNP were
slightly more common in acute guttate patients compared with
guttate £are patients (allele frequencies approximately 93% vs
90%, respectively), but the di¡erence was not statistically
signi¢cant.
PPP was neither associated to the HLA-Cwn6 allele nor any
other HLA-C allele. Twenty percent (21 of 106) of British PPP
patients had the Cwn6 allele compared with 15% (47 of 307) of
controls (OR¼1.4, 95% CI¼ 0.8^2.6, p¼ 0.30) (Table II). The
frequencies of any CDSN SNP did not di¡er signi¢cantly
between the PPP patients and the control group (Table IV). The
HCRnWWCC allele-forming SNP were slightly more com-
mon in PPP patients than in controls (approximately 50% vs
40%), but the di¡erences were not signi¢cant (OR¼1.4, 95%
CI¼ 0.9^2.3, p¼ 0.07^0.18). The only association with PPP was
for the HCR-1285nT allele (OR¼1.7, 95% CI¼1^2.7, 63% in
PPP vs 49% in controls, p¼ 0.017), but after Bonferroni
correction the result was not signi¢cant (p¼ 0.3). The
Table III. Allele associations for GP compared with control samples. Only SNP showing signi¢cant association are shown
Guttate Controls
n¼134 n¼ 309 Guttate Controls
SNP Allele Carrier frequencies Allele frequencies Pw2
b
OR (95% CI)
HLA-Cwn6 105 (83%) 47 (15%) ^ ^ 410^40 27.7 (15.8^48.5)
HCR-307a C 98 (82%) 215 (95%) 0.46 0.76
T 107 (90%) 96 (42%) 0.54 0.24 210^16 12.2 (6.3^23.4)
HCR-325 C 101 (82%) 270 (95%) 0.44 0.77
T 116 (94%) 117 (41%) 0.56 0.23 210^21 20.6 (9.7^43.7)
HCR-492 C 69 (59%) 245 (85%) 0.32 0.59
G 112 (96%) 194 (67%) 0.68 0.41 210^8 11.1 (4.4^28.1)
HCR-1249 C 73 (61%) 227 (80%) 0.35 0.54
T 108 (91%) 205 (72%) 0.65 0.46 710^4 3.8 (2.0^7.5)
HCR-1285 C 92 (79%) 267 (92%) 0.53 0.71
T 85 (73%) 148 (51%) 0.47 0.29 0.001 2.5 (1.6^4.0)
HCR-1723 G 100 (81%) 280 (94%) 0.46 0.75
T 111 (90%) 132 (44%) 0.54 0.25 210^16 10.8 (5.8^20.0)
HCR-2327 C 95 (75%) 247 (88%) 0.43 0.67
G 114 (90%) 154 (55%) 0.57 0.33 110^10 7.2 (3.9^13.4)
HCRnWWCC 102 (86%) 87 (31%) ^ ^ 910^23 13.6 (7.7^24.1)
CDSN-619 C 39 (31%) 113 (37%) 0.16 0.20
T 127 (99%) 294 (97%) 0.84 0.80 NS 4.3 (0.5^34.1)
CDSN-1243 T 60 (47%) 246 (81%) 0.25 0.53
C 125 (98%) 227 (75%) 0.75 0.47 410^7 14.1 (4.4^45.7)
CDn5 116 (93%) 143 (47%) ^ ^ 210^17 11.9 (6.1^22.9)
SNP9 T 98 (86%) 245 (99%) 0.50 0.89
C 97 (85%) 51 (21%) 0.50 0.11 710^30 22.0 (12.1^40.2)
SNP7 G 17 (15%) 255 (99%) 0.50 0.90
A 99 (85%) 51 (20%) 0.50 0.10 910^32 23.7 (13.0^43.0)
Only samples with genotyping data for the allele counted in nominator.
aAllele numbering refers to GenBank accession no. AY029160.
bAfter Bonferroni correction.
Table II. HLA-C allele frequencies of U.K. sample set
(only alleles present in ¢ve or more samples in at least one
group are shown)
PPP Guttate Control
HLA-C n¼106 n¼134 n¼ 309
n0102/3 10 (9%) 7 (6%) 19 (6%)
n0202 8 (8%) 10 (8%) 25 (8%)
n03 0 (0%) 0 (0%) 3 (1%)
n0302/4 6 (6%) 10 (8%) 37 (12%)
n0303 15 (14%) 8 (6%) 41 (14%)
n04/18 16 (15%) 12 (10%) 57 (19%)
n0501 16 (15%) 19 (15%) 56 (18%)
n0602 21 (20%) 105 (83%)a 47 (15%)
n0701/6 43 (41%) 17 (13%) 99 (33%)
n0702 25 (24%) 14 (11%) 79 (26%)
n0704 3 (3%) 5 (4%) 11 (4%)
n08 6 (6%) 9 (7%) 31 (10%)
n1202 3 (3%) 0 (0%) 8 (3%)
n1203 5 (5%) 5 (4%) 19 (6%)
n15 0 (0%) 0 (0%) 12 (4%)
n1601 6 (6%) 11 (9%) 20 (7%)
ap¼ 410^40.
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frequencies of all the genotyped SNP were similar in the
subgroup of PPP patients with concomitant PV. The study
group was, however, small (n¼19) and the resolution of
observed di¡erences would require a larger sample size. When
stratifying the PPP patients for the age of onset, no signi¢cant
di¡erence was detected in allele frequencies between patients
with early onset (o40 y) and late onset (440 y) disease (data
not shown).
The allele frequencies of the HCRnWWCC SNP in 50
Swedish PPP patients were slightly lower than in British PPP
samples (Table IV). Nineteen percent of the Swedish patients
had the HLA-Cwn6 allele, which was close to the 20% seen in
British PPP patients. The allele frequencies estimated from 124
Swedish control chromosomes (Asumalahti et al, 2002) were
similar to the frequencies in PPP patients. Eighteen percent of
control chromosomes had: HLA-Cwn6; 40% HCR-307nT; 37%
HCR-325nT; 35% HCR-1723nT; and 50% HCR-2327nG.
Sequencing of HCR in PPP patients We next sequenced
eight British and six Swedish PPP patient samples for the
coding region of the HCR gene in order to exclude possible
new PPP-speci¢c variants.We found two novel SNP, HCRn326
G-A in exon 4, which was seen in one British patient and
caused an arginine change to glutamine, and HCRn2315 G-A
in exon 18 seen in two British patients and causing an arginine
change to lysine. The two novel SNP seem to be extremely
rare, because we did not see them in any other samples when
screening the whole 106 U.K. PPP patient cohort. In the six
sequenced Swedish samples, no new SNP were detected.
Immunohistochemistry In GP, the HCR protein was
expressed particularly in the nuclei of basal keratinocytes at the
tips of dermal papillae (Fig 1a) resembling the staining found
in plaque psoriasis (Asumalahti et al, 2002). Much less HCR pro-
tein was evident in PPP samples in which occasional basal
keratinocytes bordering dermal papillae at the sides of PPP
blisters demonstrated cytoplasmic staining (Fig 1c,d). Occasional
nuclear staining was seen in suprabasal keratinocytes under old
PPP pustules (data not shown). Control sole skin was negative
except for occasional nuclei in the upper epidermis (Fig 1b).
DISCUSSION
We performed a large-scale genotyping study of the PSORS1
locus to determine if analysis of two distinct clinical variants
of psoriasis, GP and PPP, would help (i) con¢rm or exclude a
common genetic background between the diseases, and (ii), if as-
sociated, whether detailed molecular genetic analysis would help
to di¡erentiate in the role of the genes in the PSORS1 locus in
susceptibility to the psoriatic disorders.
We have con¢rmed the strong association between HLA-
Cwn6 and GP (83% vs 15% in controls) in our large British
case^control material. Recently, two new SNP at the PSORS1
locus, SNP 7 and 9, have been shown to associate with PV even
more strongly than HLA-Cwn6 (Veal et al, 2002). In this study,
these alleles showed strong association with GP, yet less so than
HLA-Cwn6. The frequencies of the alleles were almost the same
among GP patients as for the Cwn6 allele (83^85%), but in con-
trols they were slightly more common than HLA-Cwn6 (20% vs
15%). Variants at the other two PSORS1 candidate genes, HCR
and CDSN, showed a very strong association to GP. As with
PV, the CDSN association was the weakest among the three
genes (Asumalahti et al, 2002). The four SNP de¢ning the
HCRnWWCC susceptibility allele were seen in almost all GP pa-
tients (over 90%), but they were also more common in controls
than HLA-Cwn6. In addition, the results may be skewed by com-
paring the HLA-Cwn6 allele as such with separate SNP of the
HCR and CDSN genes, because HLA-Cwn6 is already com-
prised of several SNP. To overcome this problem, we examined
the frequencies of HCRnWWCC and CDSNn5 susceptibility al-
leles as a whole, a study made possible by the strong linkage dis-
equilibrium between the separate SNP alleles. As for PV, the OR
for the three genes were very similar, their 95% CI overlapping,
and the associations highly signi¢cant. The HCRnWWCC asso-
ciation was weaker than that for HLA-Cwn6, but stronger than
for CDn5. The HCRnWWCC and the CDSNn5 alleles were
more common both in patients and controls than the HLA-
Cwn6 allele. The weaker statistical signi¢cance measured as p-va-
lues and OR could be partly explained by that. Based on the
overlapping 95% CI, however, which take better into account
the allele frequency di¡erences, the genes could not be separated.
We also observed that all three susceptibility alleles tend to occur
in the same individuals, consistent with the same association to
PSORS1 for both GP and PV.To assess possible functional di¡er-
ences for a PSORS1 region candidate gene, HCR, we compared
expression patterns in GP and PV samples. The immunohisto-
chemical analysis showed highly similar patterns, consistent with
the genetic analysis.
Thus, this study would support the hypothesis that PVand GP
share the same genetic background. GP usually has an earlier on-
set than PV, which may in£uence the stronger association of
PSORS1 to GP than to PV. Furthermore, early onset psoriasis
(before age 40 y) has a stronger association to PSORS1 locus than
Table IV. Carrier and allele frequencies of HCR and CDSN PSORS1 risk SNP in PPP patients and controls
PPP (UK) PPP (Swe) Controls (UK) PPP
(UK)
PPP
(Swe)
Controls
(UK)n¼106 n¼ 50 n¼ 309
SNP Allele Carrier frequencies Allele frequencies Pw2
b
HCR-307a C 83 (89%) 46 (92%) 215 (95%) 0.69 0.74 0.76
T 47 (51%) 21 (42%) 96 (42%) 0.31 0.26 0.24 0.178
HCR-325 C 83 (89%) 48 (96%) 270 (95%) 0.69 0.77 0.77
T 47 (51%) 21 (42%) 117 (41%) 0.31 0.23 0.23 0.121
HCR-1723 G 79 (86%) 48 (96%) 280 (94%) 0.66 0.75 0.75
T 49 (53%) 23 (46%) 132 (44%) 0.34 0.25 0.25 0.126
HCR-2327 C 75 (81%) 42 (84%) 247 (88%) 0.58 0.62 0.67
G 61 (66%) 30 (60%) 154 (55%) 0.42 0.38 0.33 0.068
CDSN-619 C 32 (31%) n/a 113 (37%) 0.17 n/a 0.20
T 101 (96%) 294 (97%) 0.83 0.80 0.500
CDSN-1243 T 83 (79%) n/a 246 (81%) 0.57 n/a 0.53
C 68 (65%) 77 (75%) 0.43 0.47 0.051
Only samples with genotyping data for the allele counted in nominator.
aAllele numbering refers to GenBank accession no. AY029160.
bU.K. PPP patients vs U.K. controls.
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late-onset (after age 40 y) (Henseler and Christophers, 1985;
Guedjonsson et al, 2002; Stuart et al, 2002). The observation that
the same alleles associate with both diseases suggests that the type
of disease (PV vs GP) is controlled by factors other than the
PSORS1 locus.
The relationship between psoriasis and PPP has been contro-
versial. Several known factors support a common etiology of
the diseases, but there are also clear di¡erences between them. In
HLA association studies of PPP no consistent association with
PV associating HLA alleles (B13, B17, Cw6) has been reported
(Karvonen et al, 1975; Zachariae et al, 1977; Ward and Barnes,
1978; Rosen et al, 1982). The HLA class I typings, however, have
been made using serologic methods, which are known to be in-
sensitive for HLA-C and fail to detect many HLA-C alleles com-
pletely (Bunce et al, 1996). Furthermore, the case^control study
groups in the earlier studies have been rather small lacking the
power to detect small di¡erences between the study groups.Thus,
to date, no conclusive results for the most signi¢cant HLA anti-
gen in PV, HLA-Cwn6, are reported in PPP. For the other
PSORS1 susceptibility alleles this study is the ¢rst such study in
PPP patients.
Some evidence for the association of PPP with HLA-B8 (Ward
and Barnes, 1978), and Bw35 alleles (Zachariae et al, 1977) has been
observed in the Caucasians. Japanese PPP patients have been re-
ported to be associated with the HLA class II DR9 allele and class
III TNF-Bn2 allele, which are in linkage disequilibrium with
each other (Torii et al, 1994; Hashigucci et al, 1999). These alleles,
however, are not part of the PSORS1 risk haplotype and were
beyond our interest, which was speci¢cally focused on the
PSORS1 locus and its constituent risk alleles.
In this study, none of the three potential psoriasis susceptibility
alleles at PSORS1, HLA-Cwn6, HCRnWWCC, or CDSNn5
showed a signi¢cant association with PPP when studied in two
di¡erent populations, which speaks strongly for di¡erent etiolo-
gies or molecular mechanisms in comparison with PV or GP.
Even when considering PPP patients with concomitant PV, the
frequencies of the PV susceptibility alleles did not di¡er appreci-
ably from controls. The lack of association with PSORS1 alleles
could not be explained by the later onset of PPP compared with
GP, because the frequencies of the PSORS1 risk alleles were
even slightly lower among the PPP patients with age of onset
o40 y.
Figure1. Immunohistochemical staining using HCR antibodies on GP (A) showed strong staining in the basal keratinocytes particularly at
the tips of dermal papillae. In PPP samples (C,D) much less HCR expression was detected with only occasional basal keratinocytes bordering dermal
papillae at the sides of blisters showing staining. Normal sole skin used as a control (B) was mostly negative with a few positive nuclei in the upper
epidermis. Higher magni¢cation showed that in GP (F) mostly the nuclei of keratinocytes were stained and in PPP (G) cytoplasmic staining was more
common. (E) Pre-immune serum did not stain any skin structures.
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As the recently identi¢ed HCR gene has been shown to be
associated with PV, we sequenced this gene in 14 patients, to ex-
clude possible novel and speci¢c PPP variants; however, no such
further variants were detected. Considering the high level of
polymorphism of the HCR gene and extreme linkage disequili-
brium within the PSORS1 region (Asumalahti et al, 2000, 2002),
this result renders it unlikely that PSORS1 plays a signi¢cant part
in conferring inherited susceptibility to PPP. Thus, PPP suscept-
ibility seems to be dependent on factors outside of the PSORS1
interval. PV and PPP are likely to share common pathogenetic
steps, as suggested by their concurrence in patients; however, pro-
gression of these disorders is likely to involve genes other than
those in the PSORS1 region.These genetic data were further sup-
ported by the immunohistochemical analyses for the candidate
gene HCR, for which similar expression patterns were seen in
PV and GP in contrast to that seen in PPP.
In conclusion, this study shows unambiguously that PV and
GP are genetically indistinguishable for their association to
PSORS1, whereas PPP is a distinct genetic entity.
This study was supported by the Sigrid JuseŁ lius Foundation, Academy of Finland,
Helsinki University Hospital research funds,WellcomeTrust (R.C.T./J.N.W.N.B.),
and PPP Healthcare MedicalTrust (UK).
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